NYMXFOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
NYMOX PHARMACEUTICAL CORP
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Sep 14, 2026
$0.04+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | -238.8% | -695.1% | |
| Current ratio | – | 1.98 | 0.06 | |
| Interest coverage | 52.7× | 390.7× | -6.3× | |
| Inventory turnover | 8.4× | 0.1× | – | |
| Capex to revenue | 0.7% | 260.0% | – | |
| Diluted shares | 46M | 74M | 96M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nymox Pharmaceutical generated $23.49M from operations and spent $10.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$23.49M
Used
$10.00K
Capital expenditure$10.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$4.28M
- Cash generatingOperating cash flow above zero-$1.81M
- Return on assets improvedROA up on the prior year-716.4% → -653.7%
- Earnings backed by cashOperating cash flow above net income-$1.81M vs -$4.28M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.09 → 0.06
- No dilutionShare count did not rise94M → 96M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00